Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + veliparib + vinorelbine
- Development stage
- Unknown
- Lead developer
- Abbott
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **cisplatin**, a platinum-based chemotherapy drug that interferes with DNA replication; **veliparib**, a PARP inhibitor that blocks DNA repair; and **vinorelbine**, a vinca alkaloid that disrupts microtubule formation, preventing cell division. It is used in the treatment of advanced triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer.
02
Targets
MicrotubuleDNAPARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on cisplatin + veliparib + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + veliparib + vinorelbine.